Clearside Biomedical to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
Clearside Biomedical (Nasdaq: CLSD), a biopharmaceutical company focused on delivering therapies to the back of the eye through the suprachoroidal space (SCS®), has announced its participation in the 24th Annual Needham Virtual Healthcare Conference.
The company's leadership, including George Lasezkay, President and CEO, and Victor Chong, Chief Medical Officer and EVP of Research & Development, will engage in a fireside chat on Monday, April 7, 2025, at 12:45 p.m. ET. The presentation will be accessible via webcast through Clearside's website under the Investors section, with the recording remaining available for three months.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, CLSD declined 1.12%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
ALPHARETTA, Ga., April 01, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that George Lasezkay, PharmD, JD, President and Chief Executive Officer, and Victor Chong, M.D., MBA, Chief Medical Officer and EVP, Head of Research & Development, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025 at 12:45 p.m. ET.
A link to the live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. An archive of the webcast will be available for three months.
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®) to improve patient outcomes. Clearside’s SCS injection platform, utilizing the Company’s patented SCS Microinjector®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company’s lead program, CLS-AX (axitinib injectable suspension), is in development for the treatment of neovascular age-related macular degeneration (wet AMD). Planning for a Phase 3 program is underway. In addition, Clearside is evaluating various small molecules for the potential long-acting treatment of geographic atrophy (GA). Clearside developed and gained approval for its first product, XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the U.S. through a commercial partner. Clearside also strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. For more information, please visit clearsidebio.com or follow us on LinkedIn and X.
Investor and Media Contacts:
Jenny Kobin
Remy Bernarda
ir@clearsidebio.com
(678) 430-8206
Source: Clearside Biomedical, Inc.
FAQ
When is Clearside Biomedical's (CLSD) presentation at the Needham Healthcare Conference?
How can investors access Clearside Biomedical's (CLSD) Needham Conference presentation?
How long will Clearside Biomedical's (CLSD) Needham Conference presentation be available for replay?
Which Clearside Biomedical (CLSD) executives are participating in the Needham Healthcare Conference?
What is Clearside Biomedical's (CLSD) main technological focus?
